Null and Noteworthy
Recent articles
A monthly newsletter about neuroscience research that fails to support a hypothesis or replicates a previously proposed one.
Null and Noteworthy, relaunched: Probing a schizophrenia biomarker
This edition of Null and Noteworthy—the first for The Transmitter—highlights new findings about the auditory steady-state response in people with schizophrenia that, all within one study, somehow packed in a null result and a failed replication.
Null and Noteworthy, relaunched: Probing a schizophrenia biomarker
This edition of Null and Noteworthy—the first for The Transmitter—highlights new findings about the auditory steady-state response in people with schizophrenia that, all within one study, somehow packed in a null result and a failed replication.
The true meaning of a null result
This edition of Null and Noteworthy highlights results that reveal the difficulty in drawing definitive conclusions from data, including new findings about epidurals that contradict several others and an apparent null result on sex differences that may derive from “circular logic.”
The true meaning of a null result
This edition of Null and Noteworthy highlights results that reveal the difficulty in drawing definitive conclusions from data, including new findings about epidurals that contradict several others and an apparent null result on sex differences that may derive from “circular logic.”
Prenatal exposures; Angelman trial suspension; autistic adult well-being
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Prenatal exposures; Angelman trial suspension; autistic adult well-being
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Null and Noteworthy: Modified MRI; father findings
This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.
Null and Noteworthy: Modified MRI; father findings
This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.
Null and Noteworthy: Arbaclofen results; another oxytocin edition
New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.
Null and Noteworthy: Arbaclofen results; another oxytocin edition
New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.
Null and Noteworthy: Reader response; cerebrospinal fluid; connectivity subgroups
In this edition of Null and Noteworthy, researchers upend early interventions and diagnostic boundaries.
Null and Noteworthy: Reader response; cerebrospinal fluid; connectivity subgroups
In this edition of Null and Noteworthy, researchers upend early interventions and diagnostic boundaries.
Detecting a signal amid noise in autism early-intervention research
Studies of behavioral treatments for autism are complex and can easily be misunderstood. Here we provide some guidance.
Detecting a signal amid noise in autism early-intervention research
Studies of behavioral treatments for autism are complex and can easily be misunderstood. Here we provide some guidance.
Null and Noteworthy: Registered reports; motor measurements; viral DNA
In this edition of Null and Noteworthy, Spectrum talks with a Nature editor about the journal’s move to publish more null results.
Null and Noteworthy: Registered reports; motor measurements; viral DNA
In this edition of Null and Noteworthy, Spectrum talks with a Nature editor about the journal’s move to publish more null results.
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Null & Noteworthy: Intervention flops; neural noise; gender care
This edition takes aim at the autism-intervention evidence base with a slew of null results, plus findings that challenge a prevailing autism brain theory.
Null & Noteworthy: Intervention flops; neural noise; gender care
This edition takes aim at the autism-intervention evidence base with a slew of null results, plus findings that challenge a prevailing autism brain theory.
Explore more from The Transmitter
2025 Brain Prize honors pair of cancer neuroscientists
Michelle Monje and Frank Winkler share the $1.4 million award for their discovery of synapses between brain cancer cells and neurons.
2025 Brain Prize honors pair of cancer neuroscientists
Michelle Monje and Frank Winkler share the $1.4 million award for their discovery of synapses between brain cancer cells and neurons.
New tools help make neuroimaging accessible to more researchers
A lack of programming experience can derail experimental aspirations. But custom software packages, web-based applications and video tutorials make functional MRI concepts easier to grasp.
New tools help make neuroimaging accessible to more researchers
A lack of programming experience can derail experimental aspirations. But custom software packages, web-based applications and video tutorials make functional MRI concepts easier to grasp.
Amid confusion around U.S. science, some neuroscientists prepare to rally
Eight neuroscientists at different career stages spoke with The Transmitter about whether they plan to participate in the upcoming “Stand Up for Science” demonstrations across the United States on 7 March.
Amid confusion around U.S. science, some neuroscientists prepare to rally
Eight neuroscientists at different career stages spoke with The Transmitter about whether they plan to participate in the upcoming “Stand Up for Science” demonstrations across the United States on 7 March.